ReviewFrontiers in cellular and infection microbiology2021
Antituberculosis Therapy and Gut Microbiota: Review of Potential Host Microbiota Directed-Therapies.
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- Gut microbiome disruption in Tanzanian pulmonary tuberculosis patients: links to treatment, nutritional status, and host immunity.BMC microbiology · 2026Article
- Effect of Antitubercular Drug Macozinone (PBTZ169) on the Intestinal Microbiota and Immunity in Inbred Mice.Bulletin of experimental biology and medicine · 2026Article
- Gut microbiota and tuberculosis infection: interaction and therapeutic potential.Gut microbes · 2025Review
- Gut microbiota and tuberculosis.iMeta · 2025Review
- Insights into Autophagy in Microbiome Therapeutic Approaches for Drug-Resistant Tuberculosis.Cells · 2025Review
- Article
- Metabolic and immune consequences of antibiotic related microbiome alterations during first-line tuberculosis treatment in Bamako, Mali.Frontiers in immunology · 2025Article
- Human Gut Bacteriophageome: Insights Into Drug Resistance Mechanisms in Tuberculosis.Interdisciplinary perspectives on infectious diseases · 2025Review
- The impact of HIV antiretroviral therapy on gut microbiota: the need for well-designed longitudinal studies.Journal of infection in developing countries · 2024Review
- Sophisticated natural products as antibiotics.Nature · 2024Review
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis throughFrontiers in microbiology · 2024Article
- Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.Nature communications · 2023Article
- Gut microbiome variation in pulmonary TB patients with diabetes or HIV comorbidities.Frontiers in microbiomes · 2023Article
- The microbiome and the gut-lung axis in tuberculosis: interplay in the course of disease and treatment.Frontiers in microbiology · 2023Review
- Identifying Gut Microbiota Conditions Associated with Disease in the African Continent: A Scoping Review Protocol.Methods and protocols · 2022Article
- Antibiotic Resistance toAntibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
Abstract
Tuberculosis (TB) remains a major public health concern with millions of deaths every year. The overlap with HIV infections, long treatment duration, and the emergence of drug resistance are significant obstacles to the control of the disease. Indeed, the standard first-line regimen TB treatment takes at least six months and even longer for the second-line therapy, resulting in relapses, drug resistance and re-infections. Many recent reports have also shown prolonged and significant damage of the gut microbial community (dysbiosis) from anti-TB drugs that can detrimentally persist several months after the cessation of treatment and could lead to the impairment of the immune response, and thus re-infections and drug resistance. A proposed strategy for shortening the treatment duration is thus to apply corrective measures to the dysbiosis for a faster bacterial clearance and a better treatment outcome. In this review, we will study the role of the gut microbiota in both TB infection and treatment, and its potential link with treatment duration. We will also discuss, the new concept of "Host Microbiota Directed-Therapies (HMDT)" as a potential adjunctive strategy to improve the treatment effectiveness, reduce its duration and or prevent relapses. These strategies include the use of probiotics, prebiotics, gut microbiota transfer, and other strategies. Application of this innovative solution could lead to HMDT as an adjunctive tool to shorten TB treatment, which will have enormous public health impacts for the End TB Strategy worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.